BIO-TECHNOLOGY GENERAL ANNOUNCES ISSUANCE OF TWO NEW PATENTS.ISELIN, N.J.--(BUSINESS WIRE)--May 5, 1995--Bio-Technology General Corp. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :BTGC BTGC Bio-Technology General (stock symbol) BTGC Bukit Tinggi Golf Club (Malaysia) ) today announced the issuance of U.S. Letters Patent No. 5,403,596 relating to Factor Xa inhibitor, an anti-coagulant under development by the Company. This patent, assigned to Yissum Research and Development Company and American National Red Cross is exclusively licensed to BTG BTG BIT (Built-In Test) Target Generator BTG Bridging the Gap BTG British Technology Group BtG Betreuungsgesetz (Germany) BTG Biomass Technology Group BV BTG Begbies Traynor Group and covers broader claims than a previously issued patent relating to Factor Xa inhibitor also exclusively licensed to BTG. The Company also announced the issuance in Japan under Japanese Publication No. 87780/94 of a patent relating to plasmids for the production of eucaryotic eucaryotic see eukaryotic. polypeptides. This patent includes claims with respect to a plasmid for the production of human growth hormone human growth hormone (HGH): see growth hormone. and strengthens the patent position already established for BTG's human growth hormone in Japan. Bio-Technology General Corp. develops, manufactures and markets genetically engineered and other products for human health care. CONTACT: STRATEGIC GROWTH INTERNATIONAL Don Weinberger, 516/829-7111 or BIO-TECHNOLOGY GENERAL CORP. Leah Berkovits, 908/632-8800 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion